HeartCore gets Nasdaq extension to Oct 21, 2024 to cure bid price deficiency

HeartCore Enterprises, Inc.

Received Bid Price Notice Oct 26, 2023 for non-compliance with $1.00 minimum bid price.
Nasdaq granted additional 180-day period until Oct 21, 2024 to regain compliance.
Company may effect reverse stock split if necessary to cure deficiency.
If bid price closes at $1.00+ for 10 consecutive business days, compliance will be confirmed.
No immediate effect on listing or trading of HTCR common stock on Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.